anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To provide a hypoglycemic agent with a compound isolated from specific plant component(s) as an active ingredient, suitable as an antidiabetic having hypoglycemic activity and slight in side effects.  <P>SOLUTION: The hypoglycemic agent comprises as the active ingredient a plant belonging to Meliaceae family (e.g. Melia azedarach L., Melia azedarach var. subtripinnata), momordica charantia tea, or extract therefrom. Specifically, the extract from a plant belonging to Meliaceae family is an aqueous or organic solvent extract from the plant's leaves, fruits, branches or bark, and the extract from momordica charantia tea is an aqueous or organic solvent extract from momordica charantia belonging to Cucurbitaceae family.  <P>COPYRIGHT: (C)2008,JPO&INPIT
PURPOSE: To obtain new pharmacologically active tricyclic derivs. useful as anti-depression medicines, diuretics, antihypertensive agents, etc.  
     CONSTITUTION: The tricyclic derivs. are compds. of formula I (where X is N, S, NH or the like; Y is N, S, CH or the like; Z is N, S, C-alkyl or the like; R 1  is H or an alkyl; R 2  is H, a halogen or the like; and R 3  and R 4  are each H, OH, a lower alkoxy or the like or R 3  and R 4  bond to each other to form imino, hydroxy or the like), their pharmaceutically acceptable salts and their isomers, enantiomers and diastereoisomers separated or as mixtures, e.g. 5,10- dihydro-4,4-dioxothieno[3,2-C][2,1]benzothiazepine. The compds. of the formula I are obtd., e.g. by allowing compds. of formula II to react with aminoalkyl derivs. of formula III (where W is a reactive group such as Cl, Br or I; Alk is a 1-5C linear or branched chain alkyl; and R 5  and R 6  are each H, a lower alkyl or the like) in an org. solvent in the presence of an org. or inorg. base. 
     COPYRIGHT: (C)1994,JPO
* For adult patients with baseline (start of treatment) WBC greater than or equal to 3 x109/L, ANC greater than or equal to 1.5 x109/L, and platelets greater than or equal to 75 x109/L, adjust the dose as follows, based on nadir counts for any given cycle




• For adult patients whose baseline counts are WBC less than 3.0 x109/L, ANC less than 1.5 x109/L, or platelets less than 75.0 x109/L, base dose adjustments on nadir counts and bone marrow biopsy cellularity at the time of the nadir as noted below, unless there is clear improvement in differentiation (percentage of mature granulocytes is higher and ANC is higher than at onset of that course) at the time of the next cycle, in which case continue the current dose.

If a nadir as defined in the table above has occurred, give the next course 28 days after the start of the preceding course, provided that both the WBC and the platelet counts are greater than 25% above the nadir and rising. If a greater than 25% increase above the nadir is not seen by day 28, reassess counts every 7 days. If a 25% increase is not seen by day 42, reduce the scheduled dose by 50%.

Pediatric use information is approved for Celgene Corporation's Vidaza (azacitidine for injection). However, due to Celgene Corporation's marketing exclusivity rights, this drug product is not labeled with that information.
PROBLEM TO BE SOLVED: To obtain the subject new protein having a specific amino acid sequence, useful as a material for restoring car preventing hair damage, namely, for hair treating agents, by subjecting the hair to extraction by use of a reducing agent-contg. buffer solution. SOLUTION: This new hair epithelium-specific protein is a protein extracted from mammal hair epithelia, contains amino acid sequences of formula I (X may be any amino acid) and formula II respectively, has an amino acid composition determined by amino acid analysis and comprising 8-12mol% of cysteine, 6-10mol% of glutamic acid and 14-18mol% of aspartic acid, and has a molecular weight of 6000-12000 determined by SDS-polyacrylamide electrophoresis. This new protein is useful as e.g. a hair damage restoer effective for restoring or preventing hair damage. This protein is obtained by the following process: human hair epithelia is added to a buffer solution containing 8M urea and 2-mercaptoethanol followed by incubation at 50 deg.C for one hour, and the resultant system is mashed by use of a homogenizer followed by centrifugal separation to collect the supernatant produced.
TANK-binding kinase 1 (TBK1) is a potential therapeutic target in multiple cancers, including clear cell renal cell carcinoma (ccRCC). However, targeting TBK1 in clinical practice is challenging. One approach to overcome this challenge would be to identify an upstream TBK1 regulator that could be targeted therapeutically in cancer specifically. In this study, we perform a kinome-wide small interfering RNA (siRNA) screen and identify doublecortin-like kinase 2 (DCLK2) as a TBK1 regulator in ccRCC. DCLK2 binds to and directly phosphorylates TBK1 on Ser172. Depletion of DCLK2 inhibits anchorage-independent colony growth and kidney tumorigenesis in orthotopic xenograft models. Conversely, overexpression of DCLK2203, a short isoform that predominates in ccRCC, promotes ccRCC cell growth and tumorigenesis in vivo. Mechanistically, DCLK2203 elicits its oncogenic signaling via TBK1 phosphorylation and activation. Taken together, these results suggest that DCLK2 is a TBK1 activator and potential therapeutic target for ccRCC.
BACKGROUND: Gallstone disease (GD) is common but remains asymptomatic in most cases. However, gallstones can lead to complications like choledocholithiasis or gallbladder cancer. In this study, we analyse the common genetic risk factor for GD, the p.D19H variant in the sterol transporter ABCG8, in Polish patients with gallstones and gallbladder cancer.
METHODS: Three adult cohorts were prospectively recruited: 65 patients with gallbladder cancer, 170 obese individuals scheduled for bariatric surgery and 72 patients who underwent endoscopic retrograde cholangiopancreatography due to recurrent choledocholithiasis. The control cohort consisted of 172 gallstone-free adults. The ABCG8 p.D19H (rs11887534) polymorphism was genotyped using TaqMan assays.
RESULTS: The minor allele frequency (MAF) of the ABCG8 p.D19H polymorphism was significantly (p = .02) higher among cases with either gallstones or gallbladder cancer (MAF = 8.4%) as compared to controls (MAF = 4.0%). The highest frequency of the risk allele was detected in patients with gallbladder cancer (18.5%) and obese patients with GD (17.5%), followed by individuals with choledocholithiasis (13.9%). Notably, the p.19H variant was associated with an increased risk of developing gallbladder cancer (OR 2.76, 95% CI 1.16-6.54, p = .01) and an increased risk of GD in obese individuals scheduled for bariatric surgery (OR = 2.70, 95% CI 1.05-6.49, p = .03), but did not significantly affect the risk of choledocholithiasis.
CONCLUSIONS: The ABCG8 p.D19H common risk variant increases the risk of developing gallbladder cancer in Central Europeans and enhances the risk of gallstones in the obese. Carriers of the p.D19H variant might benefit from personalized preventive strategies, particularly regarding gallbladder cancer.
All eligible patients with histologically-confirmed advanced solid tumors will be started on sirolimus (3 mg daily) alone for the first 7 days. On day 8, patients will be randomized to receive no metformin for two weeks (through day 21). From day 22 onwards, all patients will be on combination of sirolimus and metformin. Patients who were initially not randomized to metformin XR will begin taking it at 500 mg daily with an evening meal and titrated up to 1000 mg daily after one week, as above. Each cycle will be 4 weeks.
Methods and systems for managing content related to Sustainable Development Strategies (SDS) may include a processor for receiving content comprising standardized data. The standardized data may include monetary valuations. The processor may be configured to store the received content in a storage device, and communicate with a content publication module and the storage device to publish the SDS content. In an embodiment, the processor may be configured to allow for searching of the published content by criteria based on the standardized SDS content. In an embodiment, the publication of submitted contents may be limited to a first predetermined number. The publication limit may be increased from the first predetermined number to a second predetermined number when a first predetermined threshold is reached. To encourage new quality content, additional increase in the number of contents that may be published may be allowed if additional predetermined thresholds are met.
Glucose levels will be monitored using the FreeStyle Libre devices over a 14 day period. In this time the patient will receive TPN.
Healthy Controls will complete screening and baseline N-Back and PAS-EEG. 10 HC participants will also complete the optional pilot eye tracking VPC assessment following N-Back at the Baseline visit. HC participants will not complete the 10-session course of PAS or follow-up assessments.
The use of one or more inhibitors of production of photoinduced cytosoluble keratinocytary factors for the preparation of a composition intended to prevent and/or counteract the degradation of collagen fibers induced by solar radiation with a UVA/UVB ratio 10-17. The composition is intended to inhibit the production of interstitial collagens matrix-metalloproteinase 1 (MMP-1) at the level of the dermis via a paracrine mechanism. The inhibitor is associated in the composition with a direct MMP-1 production inhibitor. The composition is adapted for oral or topical administration. Independent claims are also included for: (1) A cosmetic composition for topical application to the skin and/or the scalp comprising butyric acid, its derivatives or salts in the form of a oily or hydroalcoholic solution, an oil-in-water, water-in-oil or multiple emulsion, an aqueous or anhydrous gel, microcapsules or microparticles or ionic and/or non-ionic vesicular dispersions; (2) A cosmetic procedure intended to prevent and/or diminish and/or treat the cutaneous signs of photoinduced ageing and/or the effects of the menopause by administering to the skin the claimed composition; (3) A composition comprising the inhibitor associated with a direct MMP-1 production inhibitor; and (4) A cosmetic procedure intended to induce or stimulate the growth or hair and/or slow down its loss consisting of applying the composition to the scalp. ACTIVITY : Dermatological; Endocrine-Gen. No biological data available. MECHANISM OF ACTION : Matrix-metalloproteinase-1 (MMP-1) inhibitor.
BACKGROUND AND OBJECTIVES: Postoperative seizure control in drug-resistant temporal lobe epilepsy (TLE) remains variable, and the causes for this variability are not well understood. One contributing factor could be the extensive spread of synchronized ictal activity across networks. Our study used novel quantifiable assessments from intracranial EEG (iEEG) to test this hypothesis and investigated how the spread of seizures is determined by underlying structural network topological properties.
METHODS: We evaluated iEEG data from 157 seizures in 27 patients with TLE: 100 seizures from 17 patients with postoperative seizure control (Engel score I) vs 57 seizures from 10 patients with unfavorable surgical outcomes (Engel score II-IV). We introduced a quantifiable method to measure seizure power dynamics within anatomical regions, refining existing seizure imaging frameworks and minimizing reliance on subjective human decision-making. Time-frequency power representations were obtained in 6 frequency bands ranging from theta to gamma. Ictal power spectrums were normalized against a baseline clip taken at least 6 hours away from ictal events. Electrodes' time-frequency power spectrums were then mapped onto individual T1-weighted MRIs and grouped based on a standard brain atlas. We compared spatiotemporal dynamics for seizures between groups with favorable and unfavorable surgical outcomes. This comparison included examining the range of activated brain regions and the spreading rate of ictal activities. We then evaluated whether regional iEEG power values were a function of fractional anisotropy (FA) from diffusion tensor imaging across regions over time.
RESULTS: Seizures from patients with unfavorable outcomes exhibited significantly higher maximum activation sizes in various frequency bands. Notably, we provided quantifiable evidence that in seizures associated with unfavorable surgical outcomes, the spread of beta-band power across brain regions is significantly faster, detectable as early as the first second after seizure onset. There was a significant correlation between beta power during seizures and FA in the corresponding areas, particularly in the unfavorable outcome group. Our findings further suggest that integrating structural and functional features could improve the prediction of epilepsy surgical outcomes.
DISCUSSION: Our findings suggest that ictal iEEG power dynamics and the structural-functional relationship are mechanistic factors associated with surgical outcomes in TLE.
Anastomotic leak (AL) remains a significant complication after esophagectomy. Indocyanine green fluorescent angiography (ICG-FA) is a promising and safe technique for assessing gastric conduit (GC) perfusion intraoperatively. It provides detailed visualization of tissue perfusion and has demonstrated usefulness in oesophageal surgery. GC perfusion analysis by ICG-FA is crucial in constructing the conduit and selecting the anastomotic site and enables surgeons to make necessary adjustments during surgery to potentially reduce ALs. However, anastomotic integrity involves multiple factors, and ICG-FA must be combined with optimization of patient and procedural factors to decrease AL rates. This review summarizes ICG-FA's current applications in assessing esophago-gastric anastomosis perfusion, including qualitative and quantitative analysis and different imaging systems. It also explores how fluorescent imaging could decrease ALs and aid clinicians in utilizing ICG-FA to improve esophagectomy outcomes.
Capsules contain omega-3 fatty acids (fish oil). Dosage of 3180 mg of omega-3 fatty acids will be taken orally daily up to 16 weeks.
Immunization with PSMA peptide vaccine followed by injection of Interleukin-12 (IL-12) on Day 1 of a 21-day cycle. Additional injections of IL-12 given on Days 3 and 5 of each cycle.
Femoral version impacts the long-term functioning of the femoroacetabular joint. Accurate measurements of version are required for success in total hip arthroplasties and hip reconstructive surgeries. An automated algorithm is provided for identifying the major landmarks of the femur. These landmarks are then used to identify proximal axes and create a statistical shape model of the proximal femur. With six proximal axes selected, and 200 parameters (distances and angles between points) from the shape model measured, the best-fitting linear correlation is found. The difference between true version and version predicted by this model was 0.00°±5.13° with a maximum overestimation and underestimation of 11.80° and 15.35°, respectively. This model and its prediction of femoral version are a substantial improvement over pre-operative 2D or intra-operative visual estimation measures. Acetabular orientation is also determined by an automated algorithm using radii of curvature measurements.
<P>PROBLEM TO BE SOLVED: To provide a nucleotide sequences of vertebrate Delta gene, an amino acid sequences of its encoded protein, as well as a derivative (e.g. fragment) and an analog thereof.  <P>SOLUTION: The vertebrate Delta protein is a human protein. The fragment (and a derivative and an analog thereof) of Delta comprises one or more domains of the Delta protein, including the intracellular domain, extracellular domain, DSL domain, domain of amino-terminal to the DSL domain, transmembrane region, or one or more EGF-like repeats of a Delta protein, or any combination of the foregoing. The antibody to Delta, its derivative and analog are additionally provided. The methods of production of the Delta protein, derivative and analog, e.g., by a recombinant means, are also provided. The therapeutic and diagnostic methods and a pharmaceutical composition are provided. In specific embodiments, Delta genes isolated from Xenopus oocytes, chicken, mouse, and human, are provided.  <P>COPYRIGHT: (C)2009,JPO&INPIT
CPP-ACPF mousse (MI Paste®) was applied with a microbrush on the cervical buccal surface of each tooth for 5 minutes and it was subsequently distributed for 20 seconds with a rubber cup coupled to a low speed handpiece. Right after, a sham therapy was performed, using RAFFAELLO 980 BIO - Dental Medical Technologies - DMT S.r.l. Although the device was switched on, the hand piece did not work and the sound was emitted by a mobile phone. The tip of the laser device was positioned on two areas for each dental element, located one in the center of the cervical region and the other in the middle third of the crown.
The invention discloses a method for regenerating a dental prosthetic material and an acidic amino acid-induced demineralized dental enamel outer enamel prism thereof in situ, and belongs to the technical field of in-situ regeneration of dental enamel outer enamel prisms. The preparation method is as follows: firstly, carrying out surface calcium activation onto a dental enamel surface, i.e., grafting calcium ions; then, forming calcium carbonate stable calcium ions step by step; finally, taking calcium carbonate stable calcium ions as foundation forms to synthesize hydroxyapatite crystals. Amino acid participates in the whole process, concentration of the amino acid added in a two-step process is consistent. The hydroxyapatite crystals deposited on the surface of the demineralized dental enamel are orderly and compact in sequence, and uniform in crystal morphology, so that obvious continued growth tendency of an artificial layer can be seen. The preparation method disclosed by the invention lowers protein extracting cost and harsh restrictions on an application environment, and is wide in prospect. The material prepared by the method disclosed by the invention can be applied to cosmetic dental for filling demineralization gaps, also can be used for repairing early-stage enamel demineralization, and can be used as a combined material for bottom pulp capping pit and fissure sealing, and the like.
The purpose of this research is to conduct a randomized controlled trial with three groups to test the effectiveness of various interventions aimed at reducing risky behavior by teenagers. Two intervention groups will each receive a training intervention to reduce the chances of teen pregnancy, contraction of STIs, and abusive relationships among high risk youth in the Louisville community. The wait-list control group will receive training on the unrelated topic of community building at the same time. According to the Centers for Disease Control (CDC) Youth Risk Behavior Surveillance System (YRBSS), 50% of Kentucky high school students have participated in sexual intercourse, 37% report currently being sexually active, and 14% have reported having sexual intercourse with four or more sexual partners. Furthermore, only 41% of sexually active students reported using a condom the last time they had sex. These are risky sexual practices that may lead to HIV/STI infection, as well as unintended pregnancy, within the adolescent population. Understanding the pregnancy intentions of these adolescents is not only important with regards to adolescent pregnancy, but it is also important in light of HIV and STI infection when 6% of adolescents and young adults (\<20 years of age) in Kentucky have been reported as HIV positive since 2009. As of January 2009, Kentucky ranked 42nd for teenage births (where 1 is best) with a teenage birth rate of 56 per 1,000 girls ages 15-19 years of age. Kentucky was only slightly above Mississippi, which ranked 50th with a teenage birth rate of 68.4 per 1,000. Kentucky's teenage birth rate is higher than the national rate which is currently 41.9 per 1,000 girls ages 15-19 years of age. The most recent Kentucky teen birth rates in 2007 show that Jefferson County (52.34 per 1,000 ages 15-19) exceeds the birth rate of the nation. To address these issues, 1450 Louisville youth were given the opportunity to participate in one of two intervention curricula: called Reducing the Risk and Love Notes, or a waiting list control condition.
The invention discloses a preparation method of a risperidone freeze-dried tablet and a product thereof. The invention utilizes airflow to crush risperidone, so that the particle size D90 is controlled to be less than or equal to 30 μm. The risperidone raw material is mixed with the dry powder of the skeleton supporting agent, the flavoring agent and the taste masking agent, the electrostatic adsorption with small granularity and large specific surface area of the main drug can be removed by the mixing mode, the content loss is prevented, part of the prescription amount is added with water, the mixture is continuously stirred uniformly, the prepared binder solution is added, and the volume is fixed to the prescription amount. Homogenizing, mixing, degassing, filling, quick-freezing, forming, freeze-drying, checking and sealing, and packaging to obtain the risperidone freeze-dried tablet product. The risperidone freeze-dried tablet prepared by the invention has controllable quality, can be directly taken without water, has the disintegration time of less than 10s in 2ml of water in vitro, and is suitable for patients who are inconvenient to swallow. The preparation process is simple, the problem of dust pollution of orally disintegrating tablets obtained by traditional mixing and tabletting is avoided, continuous production can be realized, and the oxidation impurities of the freeze-dried tablets obtained by preparation are obviously smaller than those of the orally disintegrating tablets obtained by the traditional process.
BGJ398 was dosed on a flat scale of 125 mg (e.g., 1 x 100 mg and 1 x 25 mg capsules) once daily for the first 21 days of the 28-day cycle (3 weeks on, 1 week off in a cycle). A complete treatment cycle is defined as 28 days.
Shock wave therapy (SWT) is a new alternative therapy for patients with severe coronary artery disease that improves myocardial ischemic symptoms by delivering low-energy shock wave stimulation to ischaemic myocardium with low-energy pulsed waves. However, the specific mechanism of its protective effect is not fully understood, especially for the protective mechanism in cardiomyocytes after hypoxia/reoxygenation (H/R). We selected a rat H9c2 cardiomyocyte cell line to establish a stable H/R cardiomyocyte injury model by hypoxia/reoxygenation, and then used SWT for therapeutic intervention to explore its cardiomyocyte protective mechanisms. The results showed that SWT significantly increased cell viability and GSH levels while decreasing LDH levels, ROS levels, and MDA levels. SWT also improved mitochondrial morphology and function of cells after H/R. Meanwhile, we found that SWT could increase the expression of GPX4, xCT, and Bcl-2, while decreasing the expression of Bax and cleaved caspase-3, and inhibiting cardiomyocyte apoptosis and ferroptosis. Moreover, this protective effect of SWT on cardiomyocytes could be significantly reversed by knockdown of xCT, a key regulator protein of ferroptosis. In conclusion, our study shows that SWT can attenuate hypoxia-reoxygenation-induced myocardial injury and protect cardiomyocyte function by inhibiting H/R-induced apoptosis and ferroptosis, and this therapy may have important applications in the treatment of clinical myocardial ischemic diseases.